Growth Metrics

Eli Lilly (LLY) Common Equity (2016 - 2025)

Eli Lilly's Common Equity history spans 17 years, with the latest figure at $26.5 billion for Q4 2025.

  • For Q4 2025, Common Equity rose 85.92% year-over-year to $26.5 billion; the TTM value through Dec 2025 reached $26.5 billion, up 85.92%, while the annual FY2025 figure was $26.5 billion, 85.92% up from the prior year.
  • Common Equity reached $26.5 billion in Q4 2025 per LLY's latest filing, up from $23.9 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $26.5 billion in Q4 2025 to a low of -$6.2 billion in Q3 2021.
  • Average Common Equity over 5 years is $2.4 billion, with a median of -$925.8 million recorded in 2023.
  • Peak YoY movement for Common Equity: tumbled 1507.19% in 2021, then skyrocketed 93921.98% in 2022.
  • A 5-year view of Common Equity shows it stood at -$2.6 billion in 2021, then dropped by 16.62% to -$3.0 billion in 2022, then surged by 39.63% to -$1.8 billion in 2023, then skyrocketed by 884.61% to $14.3 billion in 2024, then surged by 85.92% to $26.5 billion in 2025.
  • Per Business Quant, the three most recent readings for LLY's Common Equity are $26.5 billion (Q4 2025), $23.9 billion (Q3 2025), and -$3.7 billion (Q2 2025).